The Canadian ALS Research Network (CALS) expressed disappointment at the negative outcomes of the PHOENIX Phase 3 trial for AMX0035, marketed as ALBRIOZA in Canada. Despite previous positive Phase 2 results, the 48-week study showed no significant benefit in slowing ALS progression compared to placebo. CALS recommends discontinuing AMX0035 for ALS treatment based on these findings. While frustrating, they remain hopeful for future ALS treatments and appreciate Amylyx’s support and transparency.
To read the full press release, follow the link below.
